scholarly journals Changes in Parvovirus B19 positivity rates in plasma units for fractionation: An unexpected effect of non‐pharmaceutical interventions against COVID ‐19?

Vox Sanguinis ◽  
2021 ◽  
Author(s):  
Silvia Sauleda ◽  
Maria Piron ◽  
Marta Bes ◽  
Nuria Martinez‐Llonch ◽  
Lluis Puig
Keyword(s):  
Parvovirus B19 ◽  
Unexpected Effect ◽  
Pharmaceutical Interventions

Parvovirus B19 transmitted by bone marrow

2000 ◽  
Vol 111 (2) ◽  
pp. 659-661 ◽  
Author(s):  
Erik D. Heegaard ◽  
Bodil Laub Petersen
Keyword(s):  
Bone Marrow ◽  
Parvovirus B19

Parvovirus B19-assoziierte FSGS-Rekurrenz nach Nierentransplantation?

2010 ◽  
Vol 222 (02) ◽  
Author(s):  
EC Nüsken ◽  
K Dittrich ◽  
C Plank ◽  
K Amann ◽  
J Dötsch
Keyword(s):  
Parvovirus B19

Nebenwirkungen der Substitutionstherapie

1994 ◽  
Vol 14 (02) ◽  
pp. 55-59 ◽  
Author(s):  
L. Gürtler
Keyword(s):  
Hepatitis B ◽  
Parvovirus B19

ZusammenfassungViren können über Blut und Blutprodukte übertragen werden. Blut kann nicht, Blutprodukte können bedingt inaktiviert werden und deswegen wird immer eine Restwahrscheinlichkeit der Übertragung von Infektionserregern verbleiben. Zu den heute in Europa transfusionsrelevanten Viren gehören das Hepatitis-B- und -C-Virus und die Immunschwäche-Viren. Diese drei Viren zeichnen sich durch hohe Mortalität und Chronizität der Erkrankung aus. Bedingt transfusionsrelevante Viren sind das Zytomegalievirus und das Parvovirus B19. Wegen der geringen Prävalenz nicht relevant ist das humane T-Leukämie-Virus in Mittel- und Nordeuropa, in Südeuropa kommen relevante Prävalenzen vor. Auf andere, nicht relevante Viren wird wegen ihrer geringen Bedeutung nicht getestet.

A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A

1997 ◽  
Vol 78 (05) ◽  
pp. 1352-1356 ◽  
Author(s):  
Emel Aygören-Pürsün ◽  
Inge Scharrer ◽  
Keyword(s):  
Factor Viii ◽  
Hemophilia A ◽  
Parvovirus B19 ◽  
Subjective Evaluation ◽  
Recombinant Factor Viii ◽  
Fviii Inhibitor ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Bleeding Episodes ◽  
Recombinant Fviii

SummaryIn this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously treated patients with hemophilia A (factor VIII basal activity ≤15%).Recombinant FVIII was administered for prophylaxis and treatment of bleeding episodes and for surgical procedures. A total of 3679 infusions of rFVIII were given. Efficacy of rFVIII as assessed by subjective evaluation of response to infusion and mean annual consumption of rFVIII was comparable to that of plasma derived FVIII concentrates. The incremental recovery of FVIII (2.4 ± 0,83%/IU/kg, 2.12 ± 0.61%/IU/kg, resp.) was within the expected range. No clinical significant FVIII inhibitor was detected in this trial. Five of 16 susceptible patients showed a seroconversion for parvovirus B19. However, the results are ambiguous in two cases and might be explained otherwise in one further case. Thus, in two patients a reliable seroconversion for parvovirus B19 was observed.

Fetale Parvovirus-B19-Infektionen im ersten Trimenon – Diagnostik und Therapieoptionen

2006 ◽  
Vol 66 (S 01) ◽  
Author(s):  
I Juhasz-Böss ◽  
T Frimmel-Müller ◽  
S Modrow ◽  
A Hartmann ◽  
O Ortmann ◽  
...  
Keyword(s):  
Parvovirus B19
Sign in / Sign up

Export Citation Format

Share Document